Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial

Actuate Therapeutics (ACTU) highlighted results from a pre-specified subgroup analysis of its Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic adenocarcinom. Patients treated for at least one complete cycle of therapy achieved a median overall survival of 12.5 months in the elragusib/GnP arm, compared to 8.5 months in the control arm. The analysis showed a 43% reduction in the risk of death relative to control, highlighting the significant potential impact of early disease control by elraglusib. Improved outcomes were reported in the combination versus control arms, respectively: disease control rate: 53.4% vs 44.8%, overall response rate: 37.9% vs 29.3%, and median progression-free survival: 6.9 vs 5.6 months. In patients with liver metastases, treatment with elraglusib led to a 2.5-fold increase in 1-year OS and a 38% reduction in the risk of death compared to control. While the GnP arm showed 0% OS probability at 18 months, patients on elraglusib achieved a survival probability of 13.6% OS at 18 months. Additional efficacy metrics showed improvements as follows: DCR: 36.8% vs 27.9%, ORR: 29.8% vs 19.7%, and PFS: 4.9 vs 3.9. Additional clinical benefit was observed across other subgroups.